TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndro… Read more
Market Cap & Net Worth: TG Therapeutics Inc (TGTX)
TG Therapeutics Inc (NASDAQ:TGTX) has a market capitalization of $5.00 Billion ($5.00 Billion) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3044 globally and #2056 in its home market, demonstrating a 7.95% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TG Therapeutics Inc's stock price $31.51 by its total outstanding shares 158759451 (158.76 Million).
TG Therapeutics Inc Market Cap History: 2015 to 2026
TG Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $1.89 Billion to $5.00 Billion (8.75% CAGR).
Index Memberships
TG Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.20% | #70 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.01% | #376 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.36 Trillion | 0.42% | #73 of 602 |
Weight: TG Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
TG Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TG Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
14.52x
TG Therapeutics Inc's market cap is 14.52 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
204.36x
TG Therapeutics Inc's market cap is 204.36 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.89 Billion | $152.38K | -$62.95 Million | 12429.37x | N/A |
| 2016 | $738.23 Million | $152.38K | -$78.25 Million | 4844.64x | N/A |
| 2017 | $1.30 Billion | $152.38K | -$118.48 Million | 8543.24x | N/A |
| 2018 | $650.91 Million | $152.00K | -$173.48 Million | 4282.33x | N/A |
| 2019 | $1.76 Billion | $152.00K | -$172.87 Million | 11593.62x | N/A |
| 2020 | $8.26 Billion | $152.00K | -$279.38 Million | 54333.33x | N/A |
| 2021 | $3.02 Billion | $6.69 Million | -$348.10 Million | 450.95x | N/A |
| 2022 | $1.88 Billion | $2.79 Million | -$223.81 Million | 674.37x | N/A |
| 2023 | $2.71 Billion | $233.66 Million | $12.67 Million | 11.60x | 213.98x |
| 2024 | $4.78 Billion | $329.00 Million | $23.38 Million | 14.52x | 204.36x |
Competitor Companies of TGTX by Market Capitalization
Companies near TG Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to TG Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
TG Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, TG Therapeutics Inc's market cap moved from $1.89 Billion to $ 5.00 Billion, with a yearly change of 8.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.00 Billion | +5.70% |
| 2025 | $4.73 Billion | -0.96% |
| 2024 | $4.78 Billion | +76.23% |
| 2023 | $2.71 Billion | +44.38% |
| 2022 | $1.88 Billion | -37.74% |
| 2021 | $3.02 Billion | -63.48% |
| 2020 | $8.26 Billion | +368.65% |
| 2019 | $1.76 Billion | +170.73% |
| 2018 | $650.91 Million | -50.00% |
| 2017 | $1.30 Billion | +76.34% |
| 2016 | $738.23 Million | -61.02% |
| 2015 | $1.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of TG Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.00 Billion USD |
| MoneyControl | $5.00 Billion USD |
| MarketWatch | $5.00 Billion USD |
| marketcap.company | $5.00 Billion USD |
| Reuters | $5.00 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.